(Renal Cell Carcinoma) Is Keytruda Plus Inlyta Effective? KEYNOTE-426 5-Year Follow-Up Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- July 5, 2023
- 1 min read
At ASCO 2023, held in Chicago from June 2–6, 2023, Brian I. Rini and colleagues from Vanderbilt-Ingram Cancer Center presented 5-year follow-up results from the KEYNOTE-426 Phase 3 clinical trial evaluating the efficacy and safety of pembrolizumab (Keytruda) plus axitinib (Inlyta) in treatment-naive renal cell carcinoma patients.
Trial Design:
The KEYNOTE-426 Phase 3 trial randomized treatment-naive renal cell carcinoma patients (N=861) 1:1 to:
- Pembrolizumab 200 mg + axitinib 5 mg twice daily (3-week cycle, N=432)
- Sunitinib (Sutent) 50 mg once daily
Primary endpoints were PFS and OS.
Results at median follow-up of 67.2 months:
| Endpoint | Keytruda + Inlyta | Sutent |
|---|---|---|
| 5-year OS rate | 41.9% | 37.1% |
| 5-year PFS rate | 18.3% | 7.3% |
| Median duration of response | 23.6 months | 15.3 months |
Safety:
Treatment discontinuation rate: Keytruda + Inlyta 62.2% (237/381 patients) vs. Sutent 73.9% (300/406 patients). No new safety signals were identified.
Conclusion: Based on the KEYNOTE-426 5-year follow-up analysis, Brian I. Rini and colleagues concluded that Keytruda plus Inlyta demonstrated improved 5-year OS and PFS compared to Sutent monotherapy in treatment-naive renal cell carcinoma patients, supporting its continued use as a standard of care.
Source: https://meetings.asco.org/abstracts-presentations/219855
Renal Cell Carcinoma | Immunotherapy | Keytruda | Inlyta | KEYNOTE-426
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4